YU CHIEH TSAILi, Jian-RiJian-RiLiChiu, Kun-YuanKun-YuanChiuSu, Po-JungPo-JungSuSu, Yu-LiYu-LiSuChung, Hsiao-JenHsiao-JenChungLi, Ching-ChiaChing-ChiaLiHuang, Chi-PingChi-PingHuangGuo, Jhe-CyuanJhe-CyuanGuoChen, Chuan-ShuChuan-ShuChenChang, IreneIreneChangPerrot, ValérieValériePerrotChang, Yen-HwaYen-HwaChang2025-05-232025-05-232025-04-11https://scholars.lib.ntu.edu.tw/handle/123456789/729673There is a lack of real-world evidence from Taiwan on the use of cabozantinib for advanced renal cell carcinoma (aRCC). We evaluated cabozantinib treatment for aRCC after previous antiangiogenic therapy in real-world Taiwanese clinical practice.Medical records from seven Taiwanese hospitals were retrospectively analyzed. Eligible patients were adults with aRCC who initiated cabozantinib between October 2018 and August 2021 after ≥1 antiangiogenic therapy. Patient characteristics and treatment patterns were described. Outcomes included objective response rate (ORR [complete or partial]; primary endpoint) assessed by RECIST v1.1 or local investigator assessment, progression-free survival (PFS), and tolerability.Fifty-one patients were included: 39.2 % received cabozantinib second-line, 33.3 % third-line, and 27.5 % fourth- or later-line. Mean patient age was 61.2 years; most were male (80 %), had clear-cell (80 %), metastatic (92 %) disease, and had previous nephrectomy (78 %). Sunitinib and pazopanib were the most common previous (any line) treatments (63 % and 53 % of patients, respectively). Dose reductions occurred in 47 % of patients and were more common in patients (57 %) who initiated cabozantinib at 60 mg/day than in those (33 %) who initiated at 40 mg/day (72 % vs 12 %, respectively); discontinuation rates were similar for these groups (48 % vs 47 %, respectively). Overall, ORR was 39.2 % (95 % CI: 25.8, 53.9) and median PFS was 12.4 months (95 % CI: 8.2, 16.3). Rates of serious treatment-emergent adverse events related to cabozantinib were low (7.8 %).This Taiwanese study found the real-world effectiveness and tolerability of cabozantinib after previous antiangiogenic therapy to be consistent with the results of the METEOR trial.enAdvanced renal cell carcinomaCabozantinibReal-worldTaiwanjournal article10.1016/j.jfma.2025.03.01640221295